Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose
Abstract
We report the positive results of two large prospective studies of pharmacological prevention of type 2 diabetes presented at the EASD Congress in Glasgow, September 12, 2001. In the "Diabetes Prevention Program", metformin (2 x 850 mg/day), a biguanide compound, reduces the progression from impaired glucose tolerance towards type 2 diabetes by 31% (p < 0.001) while in the "STOP-NIDDM trial", acarbose (3 x 100 mg/day), an alpha-glucosidase inhibitor, diminished it by 24% (p < 0.002). These results are, however, less marked than those obtained with lifestyle modifications including better dietary habits and increased physical exercise (-58% versus control group, p < 0.001).
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.